Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

Ensuring Innovation Act

Subscribe to Ensuring Innovation Act via RSS
Symbol of money dollar from colored pills and capsules on  green background. Expensive medicine and medical insurance

Congress Takes Aim at Reducing the Cost of Medicine

By Spencer J. Johnson on May 3, 2021
Posted in Regulatory

Two bills were signed into law on April 23, 2021, with the aim of increasing access to and education regarding generic and biosimilar medicines.

The Ensuring Innovation Act was passed with the aim to “lower the price patients pay for their prescriptions,” according to Senator Bill Cassidy, one of the co-sponsors for the bill.  The…

Blog Editors

Photo of E. Anthony FiggE. Anthony FiggMember
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • Nicole M. DeAbrantes
  • Gregory DeLassus
  • Rachel M. Echols
  • Michael Ellenberger
  • Aydin H. Harston
  • Anh-Thu Lam
  • Mary Mullins
  • Adam Nicolais
  • Jennifer P. Nock
  • Gary Prato
  • Brian Rosenbloom
  • Jake Rosvold
  • Michael Saunders
  • Alex Shaver
  • Andrew Stewart
  • Andrew J. Storaska
  • Vivian Tian
  • Sheena Wang

Recent Posts

  • PTAB Reforms Shift the Battleground: Why Ex Parte Reexaminations Are Gaining Ground as IPRs Fade
  • How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 22, 2026
  • Supreme Court to Address ‘Skinny Label’ Patent Disputes
  • FDA Proposes Sweeping Changes to Accelerate Biosimilar Development
  • Breaking the Patent Thicket: Why the Proposed ETHIC Act Could Have Big Implications on Pharma Patent Law

Rothwell Figg Blogs

  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
Rothwell, Figg, Ernst & Manbeck, P.C.
Washington, DC
901 New York Avenue, NW
Suite 900 East
Washington, DC 20001
202.783.6040
BiosimilarsIPeditors@rothwellfigg.com
Boston
10 Derne Street
Suite 302
Boston, MA 02114
617.312.3101
BiosimilarsIPeditors@rothwellfigg.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rothwellfigg.com.

Copyright © 2026, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo